Veru Inc.

Contributing Author

Recent Articles by Veru Inc.

Jun-24	Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation VERU GlobeNewswire
Jun-11	Veru to Participate in the Virtual BTIG Obesity Health Forum VERU GlobeNewswire
May-28	Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone VERU GlobeNewswire
May-08	Veru Participates in a Virtual Investor KOL Connect Segment VERU GlobeNewswire
May-08	Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress VERU GlobeNewswire
May-01	Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8 VERU GlobeNewswire